scholarly journals Phosphocalcemic responses of vitamin D3 administered intact or hypophysectomized Heteropneustes fossilis maintained either in artificial freshwater or calcium deficient freshwater.

2020 ◽  
Vol 5 (3) ◽  
pp. 15
Author(s):  
Ajay Kumar ◽  
Abhishek Kumar ◽  
ManiRam Prasad ◽  
Chandra Prakash ◽  
Sunil Kumar Srivastav
Keyword(s):  
Serum Calcium ◽  
Vitamin D3 ◽  
Calcium Level ◽  
Serum Calcium Level ◽  
Serum Phosphate ◽  
Phosphate Level ◽  
Group A ◽  
Fish Group ◽  
Group B ◽  
Group D

The serum calcium level of vehicle injected fish (group-A) exhibits no alteration throughout the experiment. Vitamin D3 administration to fish Heteropneustes fossilis exhibited hypercalcemia from day 3 to day 7 (group-B). However hypophysectomized and vehicle injected fish showed hypocalcemia from day 3 to day 7 (group-C). While hypophysectomized and vitamin D3 injected fish exhibited hypercalcemia on day 3 till the end of experiment (group -D). The serum phosphate of group A fishes is unaltered throughout experiment. The phosphate level of vitamin D3   treated fish (group-B) exhibits hyperphosphatemia from day 3 to day 7. In group C fishes exhibited a significant decrease in phosphate level throughout the experiment. While the group D fishes showed hyperphosphatemia from day 3 to day 7. In group E fishes the serum calcium level remains unaffected up to day 3 the level decreases on day 5 to day 7. In group F fishes showed hypercalcemia from day 3 to day 7. In group H fishes a progressive decrease in serum calcium level is noticed on day 3 to day 7. The group H fishes shows increase in the serum calcium level from day 3 to day 7. The serum phosphate level of group E fishes showed a decrease from day 3 to day 5. The phosphate level increases from day 3 to day 7 in group F fishes. The phosphate level exhibited a decrease from day 3 to day 7 (group G). The phosphate level increases from day 5 to day 7 of group H fishes.

Randomized phase II trial comparing different doses of the bisphosphonate ibandronate in the treatment of hypercalcemia of malignancy.

1996 ◽  
Vol 14 (1) ◽  
pp. 268-276 ◽  
Author(s):  
M Pecherstorfer ◽  
Z Herrmann ◽  
J J Body ◽  
C Manegold ◽  
M Degardin ◽  
...  
Keyword(s):  
Serum Calcium ◽  
Odds Ratio ◽  
Calcium Level ◽  
Serum Calcium Level ◽  
Randomized Phase Ii ◽  
Group A ◽  
Intent To Treat ◽  
Group B ◽  
Dose Dependent ◽  
Different Doses

PURPOSE To evaluate the hypocalcemic effect and safety of three different doses of the bisphosphonate ibandronate in tumor-associated hypercalcemia, and to identify factors predicting response. PATIENTS AND METHODS One hundred seventy-four cancer patients with a serum calcium level greater than 2.7 mmol/L (10.8 mg/dL) were enrolled onto the trial. If hypercalcemia persisted after fluid repletion, patients were randomly assigned to treatment with 0.6 mg, 1.1 mg, and 2.0 mg of ibandronate. Response, defined as restoration of normocalcemia, was evaluated by an intent-to-treat analysis. RESULTS One hundred seventy-three (99%) patients were assessable for toxicity and 151 (87%) for efficacy. The administration of 0.6 mg (group A), 1.1 mg (group B), or 2.0 mg (group C) of ibandronate led to response rates of 44%, 52%, and 67%, respectively. Significantly more patients in group C responded than in group A (P = .0276). Of the various parameters examined, only the initial serum calcium level (P < .0001; odds ratio, 0.083) and the dose of ibandronate (P = .0162; odds ratio, 2.094) correlated with response. One hundred ninety-five adverse events (AEs) were reported, 99 classified as serious and 96 as nonserious. Three serious and sixteen nonserious AEs were considered related to ibandronate treatment. The three serious AEs were one case with thrombocytopenia, one with nausea, and one with fever. CONCLUSION Ibandronate therapy led to a dose-dependent reduction in serum calcium levels. The response to ibandronate treatment correlated negatively with the initial serum calcium level and positively with the dose administered. A dose of 2 mg was necessary to achieve a response rate comparable to that in previous studies with the bisphosphonates pamidronate and clodronate. Because the incidence of drug-associated AEs was low, a dose escalation of ibandronate can be recommended for further clinical trials.

scholarly journals Serum calcium and serum phosphate levels in transfusion dependent beta thalassemia

2018 ◽  
Vol 13 (2) ◽  
pp. 54-58
Author(s):  
Mst Ariza Sultana ◽  
Qazi Shamima Akhter
Keyword(s):  
Serum Calcium ◽  
Calcium Level ◽  
High Serum ◽  
Serum Phosphate ◽  
Phosphate Level ◽  
Beta Thalassemia ◽  
Control Group ◽  
Serum Phosphate Level ◽  
Ethical Aspect ◽  
Cross Sectional

Background: Patients with transfusion dependent beta thalassemia with severeanemia require regular blood transfusion to improve quality of life. This can lead to iron overload which might cause various complications including hypocalcaemia. Objective: To estimate the serum calcium and phosphate levels in transfusion dependent beta thalassemia patients. Methods: This cross-sectional study was conducted in the Department of Physiology, Dhaka Medical College, Dhaka from July 2016 to June 2017. After fulfilling the ethical aspect, a total number of 60 subjects were selected with the age ranging from 5 to 25 years. Among them, 40 transfusion dependent beta thalassemia patients were selected as the study group and 20 age and sex matched apparently healthy individuals were considered as control group for comparison. The study population were selected from Thalassemia foundation hospital, Dhaka. Theserum calcium and phosphate levels were estimated by autoanalyzer.. For statistical analysis, unpaired Student’s‘t’ test, Chi-square test were performed as applicable. Results: In this study, serum calcium level were significantly (p < 0.001) lower and serum phosphate level were significantly (p < 0.001) higher in transfusion dependent beta thalassemia patients as compared to healthy controls. In addition, 67.5% thalassemia patients had hypocalcemia (calcium level < 8.5 mg/dl) and 85% of thalassemia patients had hyperphosphatemia(phosphate level > 4.7mg/dl). Conclusions: This study concludes transfusion dependent beta thalassemiapatients have low calcium level and high serum phosphate level which should be monitored to avoid complications related to hypocalcaemia and hyperphosphatemia. J Bangladesh Soc Physiol. 2018, December; 13(2): 54-58

scholarly journals Calcium - Phosphate Index: Considerable Indicator in Different Stages of Chronic Kidney Disease

2012 ◽  
Vol 19 (Number 2) ◽  
pp. 3-6
Author(s):  
N Y Mili ◽  
Md. E Hoque ◽  
S Akhter ◽  
N S Lovely
Keyword(s):  
Chronic Kidney Disease ◽  
Calcium Phosphate ◽  
Kidney Disease ◽  
Serum Calcium ◽  
Phosphate Level ◽  
Ckd Stage ◽  
P Index ◽  
Group A ◽  
Group B ◽  
Serum Inorganic Phosphate

Since the early 1970s. calcium phosphate (Ca-P) index has been regarded as a risk factor for extra skeletal calcification. tumoral calcinosis and increased cardiovascular event and death. The general consensus was not to exceed 70 ing2h1Lt (5.6 unno1/1,2) in chronic kidney disease. The present study was done to find out the Ca - P index in different stages of (CKB) patients to assess the risks of the patients which can be understood and be negotiated. In this study 100 of previously diagnosed chronic kidney disease patients of different stages as CKD stage Ill. IV and stage V were included. Subjects were divided into three groups according to staging of chronic kidney disease : group A (stage 111) were 34 patients, group 8 (Stage IV) were 36 and group C (Stage V) were 30 patients. Mean serum inorganic phosphate level was in group A .5.41 + 2.49. group 8 8.17 + 3.63 and in group C 10.50 + 3.06. Mean serum Calcium level in three groups were in group-A 8.36± 0.74. group- B 8.10± 0.75 and in group- C was 7.43± 1.27 ). Ca - P index was calculated by multiplying the serum calcium and phosphate level. Mean Ca-P index was in group-A 49.39+ 22.95. group B-67.93+ 31.2 and in group-C 90.76+ 24.82. Statistical analysis was done betWeen these groups and it was signifimuly higher in group B than group A ( p< 0.06. group A is group 8). in group C than group A ( p< 0.00. group A vs group C) and in ,group C than group ft ( p< .002. group B vs group C). It was found that as the renal function deteriorates gradually the Ca P index increases and it is highly significantly higher in CKD — V patient than other stages.

scholarly journals Prolactin induced cyto-architectural changes in the corpuscles of Stannius of stinging catfish, Heteropneustes fossilis acclimated to different calcium media

2021 ◽  
Vol 1 (1) ◽  
Author(s):  
Srivastav Susmita ◽  
Mishra Diwakar ◽  
Kumar Abhishek ◽  
Srivastav Sunil K ◽  
Suzuki Nobuo ◽  
...  
Keyword(s):  
Plasma Calcium ◽  
Nuclear Volume ◽  
Heteropneustes Fossilis ◽  
Corpuscles Of Stannius ◽  
Treated Fish ◽  
Group A ◽  
Fish Group ◽  
Group B ◽  
Group D ◽  
Plasma Calcium Level

Adult fish Heteropneustes fossilis were divided into 4 groups –(i) Group A: kept in artificial freshwater and daily injected intraperitoneally with vehicle; (ii) Group B: kept in artificial freshwater and were daily injected intraperitoneally with 0.1 mg/100 g body wt of oProlactin; (iii) Group C: maintained in calcium-deficient freshwater and daily injected intraperitoneally with vehicle; (iv) Group D: kept in calcium-deficient freshwater and daily injected intraperitoneally with 0.1 mg/100 g body wt of oProlactin. Blood samples were taken 2 h after the last injection on 1, 3, 5, 10 and 15 days of the treatment. Plasma calcium levels were analyzed. The corpuscles of Stannius (CS) were fixed for histological studies. Artificial freshwater: The plasma calcium levels of vehicle-injected specimens (group A) remained unaltered throughout the experiment. Following prolactin treatment (group B) the plasma calcium levels progressively increased from day 3 to day 5. The values became normocalcemic at day 10 and day 15. After day 5 following prolactin administration (group B), the nuclear volume of AF-positive cells increased and the cells were seen degranulated. After day 10, there was an increased dilatation of sinusoids and the nuclear volume of AF-positive cells showed further increase. On day 15, these changes were exaggerated. The AFnegative cells of the corpuscles of Stannius of prolactin-treated fish (group B) showed no change in their histological structure and nuclear volume. Calcium-deficient freshwater: The plasma calcium level decreased in vehicle-injected fish (group C) from day 1 to day 3 (as compared to level of the fish kept in artificial freshwater). Thereafter, the level increased from day 5 resulting in hypercalcemia at day 10 and day 15. In prolactin treated fish (group D) the plasma calcium level indicated progressive increase from day 5 to day 15. In the vehicle-injected fish (group C) the AF-positive cells of corpuscles of Stannius showed accumulati

“TO EVALUATE THE EFFECT OF SERUM VITAMIN D3 ON THE TREATMENT OF BPPV”

2020 ◽  
Vol VOLUME 8 (ISSUE 1) ◽  
pp. 21-29
Author(s):  
Sachin Jain
Keyword(s):  
Serum Calcium ◽  
Vitamin D3 ◽  
Serum Vitamin ◽  
Clinical Syndrome ◽  
High Tendency ◽  
Group A ◽  
Group B ◽  
Lottery System ◽  
The Relationship

About- Benign paroxysmal positional vertigo (BPPV) is a clinical syndrome characterized by recurrent, brief episodes of severe vertigo and rotatory nystagmus, precipitated by speci􀃶c positions of the head relative to gravity.Diagnosis of BPPV is usually based on history, clinical examination and the mechanism of vertigo has been attributed to calcium debris within the p o s te r i o r s emi - c i rc u l a r c a n a l k n ow n a s canalithiasis. The aim of the present study was to evaluate the effect of serum Vitamin D3 on the treatment of BPPV, recurrences of BPPV and the relationship between serum Vitamin D3, serum calcium and recurrence of BPPV. Method- The Prospective Randomized Single Blind Case Control Study was carried out. A total number of 80 patients were enrolled in the study. Out of this only 50 patients came for regular and complete follow up. The patients were divided randomly into two groups on the basis of a vitamin D level (ng/ml) and computer-bas ed lottery system and each group had 25 patients. Result- Out of 50 patients, group A with vit D and group B without vit D supplementation. The recurrence rate in our study of group A and group B was 8% and 12% respectively. Conclusions- From our study we concluded that in the patients of BPPV, serum Vitamin D3 and Calcium was found to be de􀃶cient and BPPV has high tendency of recurrence and de􀃶ciency of Vitamin D3 is one of the causes of recurrences of BPPV. Keywords-Vitamin D3, serum calcium, BPPV.

scholarly journals Status of Serum Level of Vitamin D3 and Its Correlation with Serum Calcium Level in Patients Referred to Sarem Hospital in Tehrantal in Tehran

2020 ◽  
Vol 5 (4) ◽  
pp. 172-179
Author(s):  
Majid Asiabanha ◽  
Behnam Younesi ◽  
Abodlrahim Absalan ◽  
Peiman Lashgari ◽  
◽  
...  
Keyword(s):  
Serum Level ◽  
Serum Calcium ◽  
Vitamin D3 ◽  
Calcium Level ◽  
Serum Calcium Level

scholarly journals Correlation of pre-operative vitamin D3 levels with post-operative hypocalcemia in patients undergoing total thyroidectomy

2019 ◽  
Vol 7 (1) ◽  
pp. 128
Author(s):  
Mallikarjuna M. N. ◽  
Arun Kumar ◽  
Ramya M. V. ◽  
Santhosh C. S.
Keyword(s):  
Vitamin D ◽  
Total Thyroidectomy ◽  
Serum Calcium ◽  
Vitamin D3 ◽  
Calcium Level ◽  
Serum Calcium Level ◽  
Serum Vitamin ◽  
Hypovitaminosis D ◽  
Preoperative Serum ◽  
Vitamin D Levels

Background: Total thyroidectomy (TT) is a commonly performed procedure for various  thyroid disorders, with parathyroid insufficiency manifesting as hypocalcaemia being a well-known complication. Albeit, vitamin D is well implicated in calcium homeostasis, the association between hypovitaminosis D and postoperative hypocalcaemia is yet to be concluded. The aim of our study is to evaluate the correlation of preoperative serum vitamin D3 levels  with occurrence of post-operative hypocalcemia in patients undergoing TT.Methods: A prospective  study  was conducted on 50 patients  undergoing TT for benign thyroid diseases from November 2016 to May 2018. Pre-operative vitamin D3 levels were estimated. Serum calcium levels was measured pre‑ and post‑operatively at 24hours, 1st week and 4th week. Serum calcium level ≤8.5 mg/dl was considered as biochemical hypocalcemia. A data of demographic, clinical, biochemical and intraoperative findings were documented and analysed.Results: Statically 14 (28%) patients developed symptomatic hypocalcemia. Out of these, 11 (78.5%) patients had preoperative vitamin D levels of <30 ng/dl (p=0.034). 24 hours postoperative serum calcium level was significantly  lesser in patients with  lower preoperative vitamin D levels (p=0.015), suggesting that postoperative  hypocalcemia (24 hr) is statistically related to pre-operative vitamin D3 levels.Conclusions: It could be concluded from our study that preoperative serum vitamin D3 levels can predict post-operative occurrence of symptomatic and/or biochemical hypocalcemia. Thus, it could be hypothesized that supplementing vitamin D preoperatively could curb the incidence of hypocalcaemia following TT. However, further relevant trials are needed to attest to this. 

COMPARATIVE STUDY IN BETWEEN INTRALESIONAL VITAMIN D3 AND INTRALESIONAL BLEOMYCIN IN THE TREATMENT OF CUTANEOUS VERRUCAE

2020 ◽  
Vol 4 (8) ◽  
Author(s):  
Shrikant . ◽  
R.D. Mehta ◽  
B.C. Ghiya
Keyword(s):  
Partial Response ◽  
Comparative Study ◽  
Recurrence Rate ◽  
Vitamin D3 ◽  
Complete Response ◽  
Recurrence Rates ◽  
Additional Advantage ◽  
Cost Effective Treatment ◽  
Group A ◽  
Group B

Background: Verruca is one of the common dermatopathologies which has multiple therapeutic options but with variable success rates, refractory cases and high recurrence rates. Nowadays, treatment with intralesional injections has gained recognition due to its effectiveness in clearing verrucae. These act by stimulating the cell-mediated immunity. Out of scores of options available for intralesional therapeutics, Vitamin D3 appears to be more promising but least evaluated. Therefore, we planned to evaluate the efficacy of intralesional Vitamin D3 in various types of cutaneous verrucae. Simultaneously the results were compared with intralesional bleomycin, also. Methods: A total of 200 patients of cutaneous verrucae with varying size and duration were included in the experimental randomized comparative study. We divided them into two groups. Group A, comprising of 100 patients, received 0.2-0.5 ml intralesional Vitamin D3 (600,000 IU, 15mg/ml) and Group B, also of hundred subjects, received intralesional Bleomycin (1 mg/ml) into the base of verrucae. A maximum of 5 verrucae were injected per session at 3 weeks interval until resolution or for a maximum of 4 sessions. Patients were followed up for 6 months after the last injection to assess the clearance status and detect any recurrence. Results: In Group A (Vitamin D3), 'Complete response', 'Partial response' and 'No response' were observed in 85.07%, 6.74% and 8.17% respectively after 4 sessions. Recurrence rate was 0.81% after 6 months. In Group B (Bleomycin), 'Complete response', 'Partial response' and 'No response' were found in 77.99%, 10.47% and 11.53% in the series. Recurrence rate was 1.71%, comparatively higher in group B. Conclusion: The efficacy of intralesional Vitamin D3 was found significantly higher as compared to intralesional Bleomycin in the treatment of cutaneous verrucae with less recurrence rates. Vitamin D3 has an additional advantage of cost-effective treatment over Bleomycin. We purpose its use, as a primary mode of treatment in various types of cutaneous verrucae. Keywords: Bleomycin, Vitamin D3, Verrucae.

Sign in / Sign up

Export Citation Format

Share Document